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patients with clinical edema and grade 2 induration, mean 
difference in dermis thickness was 1.61 mm (0.27 - 2.95, 
p=0.03). Edema was associated with a more diffuse signal and 
an indistinct demarcation against the subcutaneous tissue. 
This was more pronounced in the lower quadrants (Figure). 
 
Conclusion: High-frequency US has potential to measure 
increased dermis thickness associated with radiation-induced 
induration in breast cancer patients. Edema may increase 
dermis thickness and lead to a more diffuse US signal. 
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Purpose or Objective: Ductal carcinoma in situ (DCIS) 
represents around 20% of breast cancers (BC). Standard 
treatment after breast conserving surgery is still adjuvant 
radiotherapy (RT). Several randomized trials and meta-
analysis showed a 50% risk reduction in LR after adjuvant RT. 
The aim of our analysis was to evaluate the LR rate and 
possibly to identify a risk groups stratification for DCIS 
treatment optimization. 
 
Material and Methods: We analyzed 457 patients that 
underwent BCS and adjuvant RT between 1990 and 2012. 
Median dose to the whole breast was 50 Gy in 25 fractions; 
patients with positive/close final surgical margins received a 
tumor bed boost. We stratified patients in low risk group 
using well known risk factor for LR (n=203; age ≥50 years, 
surgical margins ≥10 mm, nuclear grade 1 -2, pT ≤25 mm), 
and intermediate-high risk group (n=254; age <50 years, 
surgical margins <10 mm, nuclear grade 3 or pT >25 mm). We 
performed also a patient startification according to Van Nuys 
Prognostic Index. Estrogen and progesterone receptors 
status, nuclear grade, and Ki-67 proliferative index were 
available for most patients. 
 
Results: The mean age was 57 years (range 33-80). Hormonal 
status was positive in 92% of patients, 83 cases (18.2%) 
received adjuvant endocrine therapy. All patients received 
postoperative RT, 198 cases (43%) received also a RT boost on 
tumor bed. 
At a median follow up time of 12 years (range 3-23), we 
observed 26 LR (5.6%). Following risk groups stratification, 
we observed seven LR (3.4%) in low risk group and nineteen 
LR (7.4%) in intermediate-high risk group (p<0.001). 
 
Conclusion: Our experience evidenced a significant 
difference in LR incidence after adjuvant RT based on our 
risk factors stratification. 
This confirms the wide heterogeneity of DCIS. Identification 
of clear subgroups of patients following risk factors is still 
lacking. Waiting for results from ongoing clinical phase 3 
trials and genomic studies, postoperative RT still remains a 
mainstay in adjuvant treatment for DCIS. 
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Purpose or Objective: Voluntary moderate deep inspiration 
breath-hold (vmDIBH) is widely used for patients with left 
sided breast cancer. The purpose of this study was to 
investigate the utility of vmDIBH in local and locoregional 
radiation therapy (RT) for patients with right-sided breast 
cancer. 
 
Material and Methods: For fourteen patients with right-sided 
breast cancer, forward IMRT plans were calculated on free-
breathing (FB) and vmDIBH CT-scans, for local- as well as 
locoregional breast treatment, with and without internal 
mammary lymph nodes (IMN). We compared dose volume 
parameters to estimate the reduction in the risk of radiation 
pneumonitis, the influence on pulmonary lung function tests 
and the risk of secondary lung cancer with the use of 
vmDIBH. 
 
Results: For local breast treatment, no relevant reduction in 
mean lung dose (MLD) was found. For locoregional breast 
treatment without IMN, the average MLD reduced from 6.5 to 
5.4 Gy (p<0.005) for the total lung and from 11.2 to 9.7 Gy 
(p<0.005) for the ipsilateral lung. For locoregional breast 
treatment with IMN, the average MLD reduced from 10.8 to 
9.1 Gy (p<0.005) for the total lung and from 18.7 to 16.2 Gy 
(p<0.005) for the ipsilateral lung. We also found a reduction 
in mean heart dose between 0.6 and 2.6 Gy in four patients; 
with a mean of 0.4 Gy for all 14 patients together (p=0.07). 
We estimate that 1 out of 100 patients will not develop 
radiation pneumonitis when breath-hold is applied during 
locoregional right-sided breast cancer treatment. For ever-
smoking women, the risk of secondary lung cancer might also 
be reduced by vmDIBH.  
 
 
 
Conclusion: Breathing adapted radiation therapy in patients 
with left-sided breast cancer is becoming widely introduced. 
As a result of the slight reduction in lung dose found for 
